Abstract
We report a case of sarcomatous transformation of a prolactin (PRL)-producing pituitary adenoma in a 27-year-old man. He originally presented with bitemporal visual disturbance, headache, and hyperprolactinemia 8 years earlier. Tumor shrinkage was confirmed by magnetic resonance imaging (MRI) during treatment with dopamine-receptor agonist. However, 3 years later transsphenoidal surgery had to be performed because of tumor re-growth. Histopathological examination revealed a PRL-producing adenoma with fibrotic changes. One year later, he presented with right-sided visual disturbance, and tumor re-growth was confirmed using MRI. He underwent transcranial surgery, followed by radiation therapy (50 Gy in 25 fractions). The histological and immunostaining features were similar in both specimens obtained from the two operations. Four years later, he presented with left-sided visual disturbance, and tumor re-growth was confirmed using MRI. The mass lesion dramatically increased in size within 2 months, and partial removal of the tumor by craniotomy was performed. The specimen was histologically diagnosed as malignant fibrous histiocytoma (MFH). Regardless of aggressive chemotherapy, his clinical symptoms and imaging findings worsened rapidly. He died 7 months after the diagnosis of MFH. Because patients with pituitary tumor undergoing radiotherapy face the possibility of developing such neoplasm, long-term follow-up is required.
This is a preview of subscription content, log in via an institution to check access.
References
Colao A, Di Sarno A, Landi ML et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574–3579
Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89:1704–1711
Ferrari CI, Abs R, Maiter D et al (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 46:409–413
Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288
Muratori M, Arosio M, Gambino G et al (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537–546
Ono M, Miki N, Amano K et al (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672–2679
Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522
Webster J, Piscitelli G, Polli A et al (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909
Berkmann S, Tolnay M, Haenggi D et al (2010) Sarcoma of the sella after radiotherapy for pituitary adenoma. Acta Neurochir 152:1725–1735
Gonzalez-Vitale JC, Slavin RE, McQueen JD (1976) Radiation induced intracranial malignant fibrous histiocytoma. Cancer 37:2960–2963
Nishio S, Morioka T, Inamura T et al (1998) Radiation-induced brain tumours: potential late complications of radiation therapy for brain tumours. Acta Neurochir (Wien) 140:763–770
Romero FJ, Ortega A, Ibarra B et al (1989) Postradiation cranial malignant fibrous histiocytoma studied by CT. Comput Med Imaging Graph 13:191–194
Sasagawa Y, Tachibana O, Iizuka H (2013) Undifferentiated sarcoma of the cavernous sinus gamma knife radiosurgery for pituitary adenoma. J Clin Neurosci 20:1152–1154
Sedney CL, Morris JM, Giannini C et al (2012) Radiation-associated sarcoma of the skull base after irradiation for pituitary adenoma. Rare Tumors 4:18–20
Asa SL (2011) Adenomas causing prolactin excess. Atlas of tumor pathology, 4th ser. Fasc 15. AFIP, Wshington DC, pp 93–108
Nagasaka T, Nakashima N, Furui A et al (2010) Sarcomatous transformation of pituitary adenoma after bromocriptine therapy. Hum Pathol 29:190–193
Littley MD, Shalet SM, Beardwell CG et al (1989) Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 70:145–160
Boelaert K, Gittoes NJ (2001) Radiotherapy for non-functioning pituitary adenomas. Eur J Endocrinol 144:569–575
Flickinger JC, Nelson PB, Martinez AJ et al (1989) Radiotherapy of nonfunctional adenomas of the pituitary gland. Cancer 63:2409–2413
Tsang RW, Laperriere NJ, Simpson WJ et al (1993) Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer 72:2227–2233
Minniti G, Traish D, Ashley S et al (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90:800–804
Wen-qing H, Shi-ju Z, Qing-sheng T et al (1982) Statistical analysis of central nervous system tumors in China. J Neurosurg 56:555–564
Cahan WG, Woodard HQ (1948) Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1:3–29
Amendola BE, Amendola MA, McClatchey KD et al (1989) Radiation-associated sarcoma: a review of 23 patients with postradiation sarcoma over a 50-year period. Am J Clin Oncol 12:411–415
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kurosaki, M., Kambe, A., Ishibashi, M. et al. A case report of sarcoma of the sella caused by postoperative radiotherapy for a prolactin-producing pituitary adenoma. Brain Tumor Pathol 31, 187–191 (2014). https://doi.org/10.1007/s10014-014-0175-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10014-014-0175-3